Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
rtx-224 save search
Global Radome Market Analysis and Forecasts Report 2023-2028: Growing Demand for Technologically Advanced Carbon Fiber Radome Systems for Next-Generation Aircraft Taking the Market to New Heights
Published: 2024-02-24 (Crawled : 00:20) - prnewswire.com
RTX | $101.5 -0.06% 6.4M
|
Electronic Technology
| Email alert
Add to watchlist
GLW M | $31.495 -0.17% 2.1M
|
Electronic Technology
| Email alert
Add to watchlist
NOC | $476.27 1.12% 830K
|
Electronic Technology
| Email alert
Add to watchlist
report heights global growing advanced market
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
ATXS | $9.66 -1.43% 530K
|
Manufacturing
|
| O: 0.0%
H: 1.41%
C: -2.19%
star-0215 immunology meeting therapeutics therapy
Despite Facing a Setback in the Covid-19 Pandemic, the Aircraft Circuit Breakers Market Set to Grow with a Stunning CAGR of 4.0% in the 2022-2031 Timeframe [270-Pages] | Interpreted by Research Dive
Published: 2023-02-24 (Crawled : 12:00) - prnewswire.com
TXT | $95.26 1.59% 520K
|
Electronic Technology
|
| O: -1.34%
H: 1.35%
C: 1.11%
RTX | $101.5 -0.06% 6.4M
|
Electronic Technology
|
| O: -0.34%
H: 0.33%
C: 0.32%
LMT | $460.39 -0.2% 1.3M
|
Electronic Technology
|
| O: 0.08%
H: 0.49%
C: 0.2%
GD | $292.32 0.35% 750K
|
Electronic Technology
|
| O: -0.36%
H: 0.64%
C: 0.61%
covid-19 research set market
A Phase 1/2 Study of RTX-224, an Engineered Red Blood Cell Expressing 4-1BB Ligand and Membrane-Bound IL-12, for the Treatment of Patients with Select Advanced Solid Tumors
Published: 2022-05-26 (Crawled : 21:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.89%
H: 10.19%
C: 10.19%
rtx-224 treatment blood phase 1
Phase 1 Trial of RTX-240, Allogeneic Red Blood Cells Engineered to Express 4-1BBL and Trans-Presented IL-15, in Patients with Advanced Solid Tumors
Published: 2022-04-08 (Crawled : 17:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.19%
H: 2.28%
C: -46.21%
rtx-240 blood trial phase 1
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
Published: 2022-04-07 (Crawled : 22:00) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.36%
H: 4.8%
C: 4.27%
rtx-240 ongoing trial therapeutics phase 1
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 2.12%
H: 20.58%
C: 19.33%
rtx-240 america research trial therapeutics phase 1 results cancer
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -3.17%
H: 2.64%
C: -6.86%
rtx-224 treatment solid tumors trial therapeutics phase 1
RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice
Published: 2021-11-12 (Crawled : 12:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: 0.0%
blood growth
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Published: 2021-07-15 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.27%
H: 5.66%
C: 3.62%
immunotherapy therapy cancer immunology preclinical pre-clinical
Anti-Tumor Effects of RTX-240: an Engineered Red Blood Cell Expressing 4-1BB Ligand and Interleukin-15
Published: 2021-07-13 (Crawled : 16:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.67%
H: 1.84%
C: -0.84%
blood
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.81%
H: 2.24%
C: 1.02%
treatment solid tumors ongoing phase 1 trial phase 2 keytruda
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published: 2021-06-04 (Crawled : 13:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.62%
H: 3.05%
C: 1.94%
treatment blood phase 1 positive rtx-321 cancer phase 3
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Published: 2021-04-12 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -1.68%
H: 2.54%
C: -5.2%
treatment phase 1 positive cancer trial rtx-321 phase 3 phase 2
A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors
Published: 2021-04-10 (Crawled : 00:20) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
| Email alert
Add to watchlist
blood solid tumors phase 1 trial phase 3 phase 2
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
Published: 2021-04-09 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.08%
H: 2.65%
C: -0.95%
solid tumors ongoing phase 1 results cancer research trial phase 3 phase 2
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
Published: 2021-03-12 (Crawled : 22:00) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
| Email alert
Add to watchlist
solid tumors ongoing phase 1 trial phase 3 phase 2
Gainers vs Losers
| 85% | 15% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.99 139.2% 64M
|
Finance
CZOO | $8.67 73.75% 23M
|
EDBL | News | $6.47 72.07% 1.9M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
HKIT | $1.345 31.86% 380K
|
Technology Services
BTCM | $3.51 30.0% 730K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.